sontuzumab
Term · Oncology and biomedicine · MLC-T-ONC-016822
A humanized monoclonal antibody directed against the tumor associated antigen (TAA) mucin-1 (MUC1), with potential antineoplastic activity. Upon administration, sontuzumab targets and binds to MUC1 expressed on the surface of tumor cells, which may activate the immune system to induce an antibody-dependent cellular cytotoxicity (ADCC) against MUC1-expressing tumor cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.
| Identifier | MLC-T-ONC-016822 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | HuHMFG1 |
| Synonyms | epitumomab |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016822",
"term": "sontuzumab",
"field": "Oncology and biomedicine",
"definition": "A humanized monoclonal antibody directed against the tumor associated antigen (TAA) mucin-1 (MUC1), with potential antineoplastic activity. Upon administration, sontuzumab targets and binds to MUC1 expressed on the surface of tumor cells, which may activate the immune system to induce an antibody-dependent cellular cytotoxicity (ADCC) against MUC1-expressing tumor cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.",
"abbreviation": "HuHMFG1",
"synonyms": [
"epitumomab"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/sontuzumab/"
}
Record 15,190 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.